Venetoclax Based Regimen for the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
This study is to investigate the therapeutic efficacy and side effect of venetoclax based regimen for relapsed or refractroy T cell acute lymphoblastic leukemia.
NCT05149378 — Acute T-Lymphocytic Leukemia
Status: Recruiting
http://inclinicaltrials.com/acute-t-lymphocytic-leukemia/NCT05149378/
Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia
In general, the percentage of complete remissions is 85 - 90 % for acute lymphoid leukemia (ALL). In developing countries, percentages are lower secondary to higher sepsis-related mortality. Although the effect of statins on inflammatory response associated with sepsis has been demonstrated, including an effect on bacterial proliferation in patients with a state of immunosuppression, their effect has not been demonstrated so far in patients with hemato-oncological cancer.
NCT05133310 — Sepsis
Status: Recruiting
http://inclinicaltrials.com/sepsis/NCT05133310/
Examining a Fast Movement Approach to Pediatric Therapy Intervention in Children and Adolescents That Have Completed Medical Treatment for Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with the peak incidences occurring in children two to five years of age. Children with ALL received neurotoxic chemotherapy agents for two to three years that causes decreased distal muscle strength and poor timing of muscle activation. After completion of medical treatment, ALL childhood cancer survivors (ALL CCS) are more likely to have an inactive lifestyle, resulting in life-long gross motor proficiency differences compared to their peers. ALL CCS typically do not utilize physical therapists' expertise after medical treatment has been completed. There are limited physical therapy (PT) intervention studies for ALL CCS.
NCT05086354 — Childhood Cancer
Status: Completed
http://inclinicaltrials.com/childhood-cancer/NCT05086354/
Impact of Cross-training on Induction Treatment Response in Acute Lymphoblastic Leukemia Adults
Despite advances in the treatment of acute lymphoblastic leukemia, the prognosis in adults is still poor, largely due to the resistance of treatment at diagnosis or early relapse. Among the strategies associated with the treatment of Acute Lymphoblastic Leukemia is rehabilitation and physical medicine in order to improve the quality of life, body composition, fitness, strength and improve the attachment and acceptance of their treatment
NCT05059847 — Acute Lymphoblastic Leukemia, Adult B-Cell
Status: Recruiting
http://inclinicaltrials.com/acute-lymphoblastic-leukemia-adult-b-cell/NCT05059847/
Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients With Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. A Dose Escalation, Open-label, Phase I Study.
Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.
NCT05054257 — Non-Hodgkin's Lymphoma, Relapsed
Status: Recruiting
http://inclinicaltrials.com/non-hodgkin-s-lymphoma-relapsed/NCT05054257/
Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia
Assessment of of the biological effects of curcumin on microbiota in children with acute lymphoblastic leukemia
NCT05045443 — Acute Lymphoblastic Leukemia, Pediatric
Status: Completed
http://inclinicaltrials.com/acute-lymphoblastic-leukemia-pediatric/NCT05045443/
Treadmill Training is an Effective Rehabilitation Program in Treatment of Children With Acute Lymphoblastic Leukemia
Purpose: The present research was conducted to study the effect of treadmill training on balance after chemotherapy in children with acute lymphoblastic leukemia. Subjects and Methods: Forty children with acute lymphoblastic leukemia included in the current research ranged of age from 8 to 12 years. The children participated in this study were assigned randomly into two equal number groups (A and B). Group (A) includes 20 children who received balance exercises, while group (B) includes 20 children who received the same balance exercises of group (A) and treadmill training. The treatment program was applied three sessions per week (60 min for every session) for 8 weeks. Balance Master System and Biodex Balance System were used to evaluate balance of all children in the three groups before and after the treatment program.
NCT05032716 — Acute Lymphoblastic Leukemia, Pediatric
Status: Completed
http://inclinicaltrials.com/acute-lymphoblastic-leukemia-pediatric/NCT05032716/
A Phase1 Study at Stanford of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
With this research study has following goals - To confirm the highest tolerable dose of palbociclib in combination with chemotherapy is safe and well-tolerated. - To learn more about side effects of palbociclib in combination with chemotherapy; - To learn more about the biological effects of palbociclib on the cells in your body
NCT04996160 — Refractory Acute Lymphoblastic Leukemia
Status: Recruiting
http://inclinicaltrials.com/refractory-acute-lymphoblastic-leukemia/NCT04996160/
A Study to Assess Minimal Residual Disease by Next-generation Sequencing of Immunoglobulin Gene Rearrangements in Pediatric B-acute Lymphoblastic Leukemia
This study aimed to investigate the performance of next-generation sequencing (NGS) techniques measuring immunoglobulin heavy chain (IgH)-variable, diversity, and joining (V[D]J) clonal rearrangements （IgH-V[D]J NGS） compared with flow cytometry (FCM) in detecting of minimal residual disease (MRD) for children with acute lymphoblastic leukemia treated with South Chinese Children Leukemia Group (SCCLG)-ALL 2016, and to predict the relapse of the disease in the early stage and to assess the prognosis, so as to provide the basis for early intervention treatment and reduce the hematological relapse and improve the survival rate.
NCT04977895 — B Acute Lymphoblastic Leukemia
Status: Recruiting
http://inclinicaltrials.com/b-acute-lymphoblastic-leukemia/NCT04977895/
Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
The overall goals of this study are to measure parents' financial distress (worry or anxiety about money) during their child's/adolescent's treatment for acute lymphoblastic leukemia and whether it changes over time, and to learn what factors are associated with changes in financial distress. Information gathered from this study will inform future intervention studies that may mitigate financial distress for parents of children/adolescents being treated for acute lymphoblastic leukemia.
NCT04928599 — Acute Lymphoblastic Leukemia
Status: Suspended
http://inclinicaltrials.com/acute-lymphoblastic-leukemia/NCT04928599/